XERS vs. IMVT, HCM, IBRX, AAPG, OGN, APLS, XENE, AMRX, MIRM, and ARWR
Should you be buying Xeris Biopharma stock or one of its competitors? The main competitors of Xeris Biopharma include Immunovant (IMVT), HUTCHMED (HCM), ImmunityBio (IBRX), Ascentage Pharma Group International (AAPG), Organon & Co. (OGN), Apellis Pharmaceuticals (APLS), Xenon Pharmaceuticals (XENE), Amneal Pharmaceuticals (AMRX), Mirum Pharmaceuticals (MIRM), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical products" industry.
Xeris Biopharma vs. Its Competitors
Immunovant (NASDAQ:IMVT) and Xeris Biopharma (NASDAQ:XERS) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their community ranking, dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.
In the previous week, Xeris Biopharma had 2 more articles in the media than Immunovant. MarketBeat recorded 10 mentions for Xeris Biopharma and 8 mentions for Immunovant. Immunovant's average media sentiment score of 1.30 beat Xeris Biopharma's score of 0.50 indicating that Immunovant is being referred to more favorably in the media.
47.1% of Immunovant shares are owned by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are owned by institutional investors. 5.9% of Immunovant shares are owned by company insiders. Comparatively, 6.5% of Xeris Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Immunovant has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500. Comparatively, Xeris Biopharma has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500.
Immunovant currently has a consensus price target of $38.33, indicating a potential upside of 137.36%. Xeris Biopharma has a consensus price target of $6.25, indicating a potential upside of 42.69%. Given Immunovant's stronger consensus rating and higher probable upside, research analysts plainly believe Immunovant is more favorable than Xeris Biopharma.
Xeris Biopharma has higher revenue and earnings than Immunovant. Xeris Biopharma is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.
Xeris Biopharma received 16 more outperform votes than Immunovant when rated by MarketBeat users. However, 77.19% of users gave Immunovant an outperform vote while only 69.81% of users gave Xeris Biopharma an outperform vote.
Immunovant has a net margin of 0.00% compared to Xeris Biopharma's net margin of -33.69%. Xeris Biopharma's return on equity of 0.00% beat Immunovant's return on equity.
Summary
Immunovant and Xeris Biopharma tied by winning 9 of the 18 factors compared between the two stocks.
Get Xeris Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding XERS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Xeris Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:XERS) was last updated on 6/12/2025 by MarketBeat.com Staff
Buy XERS Stock Free XERS Stock Alerts